NorthWest Biotherapeutics Inc (NWBO)

[mike00h]

For any new NWBO investor, do not miss the following items to help you understand background on this company.

1. A fellow named Tom Baxendale put together this history and summary. It’s from last May so it could use an update, but it's a great resource:
https://drive.google.com/file/d/1zr8aHIN5ZZLO9wBf4HlJTc-C-mfajb0w/view

2. The Journal of the American Medical Association published on November, 2022:
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847?resultClick=1

3. Nature published this, also validating DCVax efficacy: https://www.nature.com/articles/s41420-023-01782-7

4. NWBO alleges market manipulation, filed a civil lawsuit. Top Wall Street law firm takes the case on contingency. Progress here:
https://www.courtlistener.com/docket/66579590/northwest-biotherapeutics-inc-v-canaccord-genuity-llc/

5. This is some recent commentary:
https://www.reddit.com/r/wallstreetbets/comments/1995j9e/the_american_system_profits_over_life_a_tiny/?sort=new

6. Some credible doctors talking about their results and experience:

7. NWBO filed for regulatory approval from MHRA (Great Britain) on December 20, 2023. They seem to have intentionally obscured their timeline for approval. Actually, it resembles bullshit. The consensus on this board is we will see the approval this year. How soon is anyone’s guess. They announce here, twice a month. But you will almost certainly hear as soon as it happens. https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024

BE SCEPTICAL! A huge amount of fear, uncertainty, doubt (FUD) and outright lies are posted on this board.

While this link doesn’t directly address NWBO, it does give a lot of information about the ‘big pharma’ arena and the patent cliffs facing all the players with cancer treatments. Don’t miss the chart, about half way down showing who has what and when it will fall off the cliff.

https://www.barrons.com/articles/big-pharma-stocks-investors-mistakes-90e3c575?st=y83h54zjsuabk98&reflink=article_email_share